Compare Adaptive Biotechnologies Corp (ADPT) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.05 (market cap $4.04B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.94. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | PDBC | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | — |
52-Week High | $25.45 | $18.91 |
52-Week Low | $12.30 | $12.90 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
PDBC trades at $17.87, up 0.22% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on diversified commodities, avoiding K-1 tax forms, and has seen strong institutional inflows, including a 150.6% position increase by Geneos Wealth Management in Q1 2026 (SEC filing, 2026-07-19). Recent news highlights commodities' role as an inflation hedge, with PDBC returning 37% since March 2024, though momentum has weakened recently (Seeking Alpha, 2026-06-11).
The outlook for PDBC is supported by geopolitical tensions and inflation hedging demand, but risks include commodity price volatility and Middle East conflicts. Wall Street sentiment is mixed, with a recent downgrade to hold due to fading momentum, yet institutional interest remains strong, indicating long-term confidence in commodities exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
